GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » ROIC %
中文

Illumina (Illumina) ROIC % : -7.82% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Illumina ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Illumina's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -7.82%.

As of today (2024-04-24), Illumina's WACC % is 12.25%. Illumina's ROIC % is -2.52% (calculated using TTM income statement data). Illumina earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Illumina ROIC % Historical Data

The historical data trend for Illumina's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina ROIC % Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.11 11.69 -1.22 3.02 -2.49

Illumina Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.35 0.10 -8.08 2.81 -7.82

Competitive Comparison of Illumina's ROIC %

For the Diagnostics & Research subindustry, Illumina's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's ROIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's ROIC % distribution charts can be found below:

* The bar in red indicates where Illumina's ROIC % falls into.



Illumina ROIC % Calculation

Illumina's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-222 * ( 1 - -3.94% )/( (10448 + 8063)/ 2 )
=-230.7468/9255.5
=-2.49 %

where

Illumina's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-608 * ( 1 - -4.79% )/( (8229 + 8063)/ 2 )
=-637.1232/8146
=-7.82 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Illumina  (NAS:ILMN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Illumina's WACC % is 12.25%. Illumina's ROIC % is -2.52% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Illumina ROIC % Related Terms

Thank you for viewing the detailed overview of Illumina's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (Illumina) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Executives
Aimee L Hoyt officer: SVP, Chief People Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen director, officer: Chief Executive Officer 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi officer: SVP Product Development 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno director C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen officer: VP, Chief Accounting Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell officer: Sr VP & General Counsel 5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank officer: Chief Public Affairs Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo officer: SVP Chief Medical Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins officer: SVP, Chief Information Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels officer: Chief of Global Operations 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley officer: President & CEO 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121

Illumina (Illumina) Headlines

From GuruFocus

Q3 2023 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc Acquires Grail Inc Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc Inaugural ESG Investor Event Transcript

By GuruFocus Research 01-23-2024